Life Science Services

Life Science Services Experience

Clairvest is the preferred equity partner of choice in the life science services space. We are not focused on obtaining control of a company. We seek to partner with existing entrepreneurs who are looking to grow their business. This offers more flexibility to our operating partners and provides the necessary capital to accelerate a company’s growth plans without getting in the way.

Life Science Services

We are seeking to invest in companies providing high value-add services to pharmaceutical and biotech companies, including CROs, CDMOs, labs, clinical research sites and commercialization services.

“If you are an entrepreneur in the space or have any acquisition opportunities in the Life Science Services space, please contact Sebastien Dhonte.

2.9x

Multiple on Invested Capital

80%

EBITDA Growth

LSNE is a contract manufacturing organization (CMO) focused on providing lyophilization (freeze-drying) services to biotech, pharmaceutical and medical device manufacturers.

View Portfolio Company

years in business

Key executive level hires made within first six months of investment

Boca Biolistics is a leading biosamples company focused on the procurement, storage, and sale of human biological samples (specializing in infectious diseases and oncology) used for clinical trials and diagnostic development.

View Portfolio Company

Our Investment Criteria

North America based
Established customer relationships
Track record of regulatory compliance
Successful customer inspections

Growth Story about LSNE

Navigating the FDA with a Reliable Equity Partner

Learn how LSNE transitioned successfully to long-run commercial manufacturing

Industry Team

Life Sciences Advisory Board

When evaluating potential investment opportunities, these accomplished entrepreneurs and business leaders provide unique insight into relevant industry issues and company specific matters that help us move forward more decisively. They are also available to provide guidance and open doors for our portfolio companies.